HLA-C and neoplasm: By modifying patients' T cells to express CARs—composed of antibodies and T cell receptors—on their surface, these cells can recognize tumor-associated antigens (TAAs) in an MHC-independent manner, thereby inducing the identification and destruction of tumor cells [106, 107].